China approves two Covid-19 experimental vaccines for clinical trials


Published on:

                La Chine a approuvé des tests humains à un stade précoce pour deux vaccins expérimentaux pour lutter contre le nouveau coronavirus qui a tué plus de 100 000 personnes dans le monde, ont rapporté mardi les médias d'Etat Xinhua.

Les vaccins sont développés par une unité basée à Pékin de Sinovac Biotech cotée au Nasdaq, et par le Wuhan Institute of Biological Products, une filiale du groupe national China National Pharmaceutical Group.

In March, China gets the go-ahead for another clinical trial for a coronavirus vaccine candidate developed by the Chinese Academy of Military Medical Sciences and the listed biotechnology company HK CanSino Bio, shortly after the drug developer American Moderna said it had started human testing for their vaccine with the National Institutes of Health in the United States.

Vaccine needed to stop the virus from spreading

The World Health Organization (WHO) said on Monday that a safe and effective vaccine would be needed to completely stop the spread of Covid-19, which has killed more than 114,000 people worldwide.

“Our global connectivity means that the risk of re-introduction and resurgence of Covid-19 will continue,” said WHO director-general Tedros Adhanom Ghebreyesus, during a virtual briefing from Geneva, stressing that “ultimately, development and the delivery of a safe and effective vaccine. will be required to completely stop transmission. “

(FRANCE 24 with REUTERS and AFP)



Please enter your comment!
Please enter your name here